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Role of Renal Metabolism in Risk
to Toxic Chemicals
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Department of Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan
The kidneys are capable of carrying out extensive oxidation, reduction, hydrolysis, and conjugation reactions. Renal cortex has high activities of
cytochrome P450 and glutathione (GSH) S-transferase. In contrast, renal medulla has high activity of prostaglandin synthetase, which can catalyze
co-oxidation of xenobiotics. While these pathways are found in many tissues and at higher activities than in kidney, several key enzymes of the mer-
capturic acid pathway are found at especially high activities in cells of the renal proximal tubule. Investigations over the last two decades demon-
strated that GSH conjugation is not only a mechanism for detoxification of reactive electrophiles. Rather, metabolism of GSH S-conjugates to the
corresponding cysteine S-conjugates represents a branch point: cysteine S-conjugates may be metabolized by the cysteine S-conjugate N-acetyl-
transferase to mercapturic acids, which are nontoxic and are excreted, or they may be substrates for the pyridoxal phosphate-dependent cysteine
conjugate ,B-lyase, which catalyzes either a n-elimination or a transamination reaction to produce unstable thiols. These thiols rearrange to form
potent acylating species that can covalently bind to cellular macromolecules, thereby producing cytotoxicity, mutagenicity, and carcinogenicity. In
addition to the ,B-lyase, two other renal enzymes, L-2-amino (2-hydroxy) acid oxidase and cysteine conjugate S-oxidase, can bioactivate chemicals to
produce nephrotoxic species. Several halogenated alkanes and alkenes are bioactivated by these pathways. These findings show that mammalian
kidney is highly active in bioactivation of xenobiotics. Although the properties of the corresponding enzymes in humans may differ, it is clear that
renal metabolism can be a critical determinant of risk to chemical injury. - Environ Health Perspect 102(Suppl 11):75-79 (1994)
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Introduction
The traditional view of renal function is
that the kidneys act as filters to remove
toxic waste products from the blood via
glomerular filtration. Reabsorption and
secretion processes on plasma membranes
of the epithelial cells allow useful metabo-
lites and electrolytes to be conserved and
waste products to be excreted. In addition
to these basic functions, the kidneys are also
active metabolically, particularly with
respect to drug metabolism. One factor that
complicates study ofrenal drug metabolism
is nephron heterogeneity, which is
expressed as differences in metabolism,
transport, morphology, and physiologic
function in the various cell populations.
While the liver has been the focus of
most drug metabolism studies and is quan-
titatively the most important site ofmetab-
olism for most xenobiotics, the kidneys are
also capable ofcarrying out extensive oxi-
dation, reduction, hydrolysis, and conjuga-
tion reactions (1,2). Enzyme systems
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Table 1. Drug metabolism enzymes in kidney.
Phase enzymes Phase II enzymes Ancillary enzymes
Cytochrome P450 Esterases GSH peroxidase
Microsomal FAD-containing monooxygenase N-Acetyltransferase Catalase
Alcohol and aldehyde dehydrogenases GSH S-transferase NADPH:Quinone oxidoreductase
Epoxide hydrolase Thiol S-methyltransferase NADPH-generating pathways
Prostaglandin synthetase UDP-Glucuronosyltransferases Superoxide dismutase
Monoamine oxidase Sulfotransferases GSSG reductase
Abbreviations: FAD, flavin adenine dinucleotide; GSH, reduced glutathione; GSSG, glutathione disulfide; UDP, uri-
dine 5'-diphosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate.
similar to those present in liver and other
extrarenal tissues are involved in renal drug
metabolism (Table 1). An important differ-
ence between the kidney and other tissues,
however, is that many ofthe drug metabo-
lism enzyme systems are differentially dis-
tributed among the nephron cell
populations (3-5). For example,
cytochrome P450 is found exclusively in
renal cortex, and prostaglandin synthetase,
which catalyzes co-oxidation of several
drugs and xenobiotics, is found in the
medulla. As a consequence of this hetero-
geneity, a given metabolic pathway may be
undetectable or detectable at very low
activities in whole kidney homogenates but
may be observable at significant rates when
specific nephron cell types are employed as
a biological source. Thus, renal metabolism
of many chemicals is localized to specific
cell types. Although other tissues also
exhibit heterogeneity, few do so to the
same extent as the kidneys.
Table 2. Factors contributing to nephrotoxicity.
1. High renal blood flow. Kidneys comprise 1% of
total bodyweight but receive 25% of cardiac
output.
2. Concentration of chemicals in intraluminal fluid.
3. Reabsorption, secretion, or both of chemicals
through tubular cells.
4. Biotransformation of protoxicants to reactive
intermediates.
5. Proximal tubules as specific targets: membrane
(brush-border, basal-lateral) transport systems,
high content of bioactivation enzymes.
6. Medullarythick ascending limb: poor oxygenation
of medulla, susceptibility to hypoxic injury.
From the brief discussion above, it
should be apparent that the kidneys can
metabolize drugs efficiently. In many cases,
metabolism yields a product that is more
toxic than the parent compound. Because
ofthis bioactivation and because ofseveral
other factors (Table 2), the kidneys are often
target organs for many toxic chemicals. This
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target organ specificity can be attributed to
the basic characteristics ofrenal physiology
such as high blood flow, glomerular filtra-
tion, and a large array of membrane trans-
port systems for organic molecules.
Nephron heterogeneity also comes into
play because the various cell populations
are differentially susceptible to chemical
and pathological injury (6).
Renal drug metabolism pathways and
their role in bioactivation have been
reviewed by several groups during the last
decade (1,2,7-12). The primary focus of
this article will be to consider pathways of
renal metabolism, particularly the gluta-
thione (GSH) conjugation pathway, that
contribute to xenobiotic toxicity and are
thus important factors in risk assessment.
Metabolism of GSH S-conjugates of
numerous halogenated hydrocarbons to
cysteine S-conjugates provides a branch
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Figure 1. Interorgan processing of GSH S-conjugates. Scheme showing the interaction of metabol
lung, liver, intestine, and kidney in overall processing of chemicals (RX) by GSH conjugation. Arrov
lined compartments (i.e., bile, plasma, etc.) indicate the route by which metabolites are transloc
organs. Abbreviations: RX, parent compound; RSG, GSH S-conjugate; RSCys, cysteine S-conjuga
N-acetylcysteine S-conjugate (= mercapturic acid); RS-, reactive thiolate anion generated in kidney
nephrotoxicity; RSCH3, thiomethyl derivative.
alternative most mammalian tissues have GSH S-
abolites are transferase activity, the liver has the highest
:hese differ- levels in the body and is quantitatively the
d regulated most important site ofGSH conjugate for-
Lt role renal mation (15). In rats, rabbits, and mice,
ssment. hepatocytes contain minimal activities ofy-
glutamyltransferase, which is the only
it enzyme that can hydrolyze the y-glutamyl
tics peptide bond of GSH and GSH S-conju-
( illustrates gates (15). Liver cells actively extrude GSH
il to under- and GSH S-conjugates into plasma and
plays a role bile for translocation to kidney and small
(13,14). intestine, respectively. The GSH S-conju-
;H S-conju- gates that are secreted into bile are
rolving the degraded to cysteine S-conjugates by y-glu-
ymes local- tamyltransferase and dipeptidases, which
). The pat- are present at relatively high levels in biliary
determined epithelium (16). Metabolites from the
distribution small intestinal epithelium are returned to
and ofthe the liver via the portal vein (enterohepatic
Although circulation). Ultimately, metabolites that
are primarily in the form ofeither cysteine
or N-acetylcysteine S-conjugates (although
some GSH S-conjugates are also present)
are delivered via the circulation to the kid-
neys. The presence ofglomerular filtration
and active transport systems on both
brush-border and basal-lateral plasma
membranes produces high intracellular
concentrations ofthese conjugates (17-21).
Once inside the renal epithelial cell, the
ultimate toxic metabolite is generated. The
prevailing view, therefore, is that GSH
conjugation occurs in the liver but the
reactions that are critical to generation of
toxicity occur within the target organ. A
study by Koob and Dekant (22), however,
suggests that intrarenal formation of the
[RS-] GSH S-conjugate ofhexafluoropropene is
directly associated with nephrotoxicity and
that the GSH S-conjugate formed in the
Toxict . liver is excreted in the bile and does not ToxiciWy reach the kidneys and, therefore, does not
cause nephrotoxicity. This finding suggests
that the exact pattern ofinterorgan metab-
olism may vary, possibly depending on the
chemical properties ofthe particular chem-
ical. In any case, however, the ultimate
toxic metabolite must be generated by
intrarenal metabolism.
After the GSH S-conjugate is metabo-
lized to the corresponding cysteine S-con-
jugate, either extrarenally or intrarenally,
several alternative reactions are possible
(Figure 2). The cysteine S-conjugate may
be N-acetylated to form the mercapturic
lic pathways in acid. Mercapturates generally are highly
vs with under- polar, chemically stable, and excreted.
cated between However, most mammalian cells, includ-
ite; RSNAcCys, ing renal cells, have deacetylase activities
ythat produces that can regenerate the cysteine S-conju-
gate. For many compounds, the cysteine
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Figure 2. Pathways of GSH S-conjugate metabolism. Scheme showing the mercapturic acid pathway and the alter-
native reactions possible for glutathione S-conjugates and cysteine S-conjugates. Abbreviations: RX, parent com-
pound; HX, leaving group; RSG, GSH S-conjugate; RSCys, cysteine S-conjugate; RSCysNAc, N-acetylcysteine
S-conjugate (mercapturate); GSTase, glutathione S-transferase; GGTase, y-glutamyltransferase; DPase, dipepti-
dase; NAcTase, cysteine S-conjugate N-acetyltransferase; DeAcase, deacetylase; ,B-lyase, cysteine conjugate ,B-
lyase; S-oxidase, cysteine conjugate S-oxidase, HAO, L-2-hydroxy (2-amino) acid oxidase.
S-conjugate is a substrate for renal
enzymes generating reactive metabolites
that produce toxicity. The localization of
transport systems that deliver the conju-
gates to kidney cells and the presence of
enzymes that act on these conjugates
within those cells determines the target site
specificity of injury. It should be noted,
however, that some GSH or cysteine S-
conjugates do not require further metabo-
lism to exert toxicity. Rather, these
conjugates are chemically unstable and
form reactive episulfonium ions that can
bind covalently to cellular macromolecules
and produce toxicity (23). 1,2-
Dihaloethanes produce nephrotoxicity and
nephrocarcinogenicity by this mechanism.
Although both the GSH and the cysteine
S-conjugate can alkylate cellular macro-
molecules (24), it is not known which
conjugate is 1,2-dichloroethane's primary
alkylating agent in vivo.
Cysteine Conjugate ,-Lyase-
dependent Bioactivation
Several haloalkyl or haloalkenyl cysteine S-
conjugates are substrates for a pyridoxal
phosphate-dependent enzyme found in
renal cytosol and mitochondria. This
enzyme cleaves the carbon-sulfur bond,
thereby generating a reactive, sulfur-con-
taining compound (25-27). All the conju-
gates that are substrates have the common
chemical property of possessing a good
leaving group on the 13-carbon atom, hence
the name 1-lyase. Cytosolic 1-lyase has
been purified to homogeneity from rat kid-
ney (28), from bovine kidney (29), and
from human kidney (30).
The renal cytosolic enzyme is identical
to glutamine transaminase K (28). This
suggests that the 1-lyase, in addition to
catalyzing a 1-elimination reaction (Figure
3, reaction la), might also catalyze a
transamination reaction (Figure 3, reaction
lb) to generate the corresponding 2-keto
acid (31,32). This hypothesis was correct.
Additionally, the observation that an addi-
tion of exogenous 2-keto acids both stimu-
lated 1-lyase activity and potentiated the
cytotoxicity of S-(1,2-dichlorovinyl)-L-cys-
teine (DCVC) in isolated rat kidney cells
indicated that the keto acid/amino acid sta-
tus could have a regulatory function (31).
Detailed studies with renal subcellular frac-
tions (31) and with purified 13-lyases
(28-30) showed that the pyridoxal phos-
phate moiety on the enzyme can get
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Figure 3. Cysteine conjugate f3-lyase: 13-elimination
versus transamination. Scheme showing alternate
pathways by which the cysteine conjugate f-lyase
produces reactive metabolites. Reactions: la, ,B-elimi-
nation; lb, transamination; 2, retro-Michael reaction.
Abbreviations: R, haloalkyl or haloalkenyl group; E-PLP,
pyridoxal phosphate form of ,B-lyase; E-PMP, pyridox-
amine phosphate form of f-lyase; KA, 2-keto acid; AA,
2-amino acid.
trapped in the pyridoxamine phosphate
form in the absence ofa keto acid acceptor.
The best keto acid acceptors are those with
relatively hydrophobic substituents on the
1-carbon such as 2-keto-4-methiolbu-
tyrate, phenylpyruvate, and 2-keto
octanoate (28,31). In either the case of 1-
elimination or transamination, the ultimate
toxic metabolite is the same, as the keto
acid analogue is chemically unstable and
spontaneously releases the reactive thiolate.
Although the kidney is the target organ,
1-lyase activity is also present in liver,
where it is a catalytic property ofkynureni-
nase (32). A significant amount of 13-lyase
activity is also present in the intestinal
microflora (33). This emphasizes that
other factors besides the presence ofthe 1-
lyase in kidney cells are necessary to deter-
mine the tissue and cell type specificity of
cysteine S-conjugate toxicity. As discussed
above, membrane transport processes and
the presence ofdetoxification pathways are
two other important factors in susceptibil-
ity to injury.
13-Lyase activity is also present in renal
mitochondria (25-27). The function and
regulation of the mitochondrial activity is
more complex than that of the cytosolic
form, as there appears to be at least two
mitochondrial 1-lyases, one on the outer
membrane (26) and one in the matrix
compartment that is identical with matrix
glutamine transaminase K (34). There is
some evidence suggesting that the multiple
13-lyases have different substrate
specificities toward both cysteine S-conju-
gates and 2-keto acids (31,34).
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Figure 4. Renal metabolism of cysteine S-conjugates
by L-2-hydroxy (2-amino) acid oxidase (HAO).
Reactions: 1, HAO; 2, retro-Michael reaction.
Abbreviations: R, haloalkyl or haloalkenyl group; E-
FMN, flavin mononucleotide form of HAO.
Alternative Bioactivation
Enzymesfor Cysteine
S-Conjugates
Rat kidney cytosol and peroxisomes con-
tain an L-2-hydroxy (2-amino) acid oxidase
(HAO) that can also metabolize cysteine S-
conjugates (Figure 4). The HAO contains
flavin mononucleotide as a cofactor and
catalyzes the oxidation of L-2-amino acids
and L-2-hydroxy acids to the correspond-
ing iminium ions and 2-oxo acids, respec-
tively, with concomitant reduction of
molecular oxygen to hydrogen peroxide
(35). In mammalian species besides the rat,
the enzyme acts strictly on L-2-hydroxy
acids. This pathway, which has been
demonstrated to function in the bioactiva-
tion and cytotoxicity ofseveral cysteine S-
conjugates and analogues in isolated rat
kidney cells (36) and with purified P-lyase
(28), may only be ofrelevance to studies in
the rat because humans lack the activity.
Sausen and Elfarra (37) have recently
described an additional enzyme, a cysteine
conjugate S-oxidase, that metabolizes cys-
teine S-conjugates to the corresponding sul-
foxides (Figure 5, reaction 1). The sulfoxide
can rearrange and, via a retro-Michael reac-
tion (Figure 5, reaction 2), produce a
sulfenic acid that can covalendy bind to cel-
lular macromolecules. The enzyme activity
is dependent on reduced nicotinamide ade-
nine dinucleotide phosphate and oxygen,
and contains a flavin cofactor. Differences in
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Figure 5. Renal metabolism of cysteine S-conjugates
by cysteine S-oxidase. Reactions: 1, cysteine S-oxi-
dase; 2, retro-Michael reaction. Abbreviation: R,
haloalkyl or haloalkenyl group.
tissue distribution, substrate specificity, and
other biochemical properties suggest that
the S-oxidase is distinct from the microso-
mal flavin-containing monooxygenase.
Although sulfoxidation may be a major
pathway for generation of terminal oxida-
tion products of cysteine S-conjugates in
vivo, the sulfoxide of DCVC is a potent
nephrotoxin (38) and is highly reactive
toward nucleophiles such as GSH (39).
The quantitative importance of this path-
way in cysteine S-conjugate nephrotoxicity
is unknown at present.
Strategiesfor Demonstration
of Role of Bioactivation
Pathways in Nephrotoxicity
To demonstrate the requirement for the
bioactivation reactions described above,
particularly the j-lyase, the strategy has
been to imply specific enzyme inhibitors,
cosubstrates, and nonmetabolizable ana-
logues and then examine effects on toxicity,
both in vivo and in vitro (Figure 6). The
dependence ofmembrane transport via the
probenecid-sensitive organic anion trans-
port system has been shown by the ability
ofprobenecid to prevent or diminish toxic-
ity. Specific inhibitors of y-glutamyltrans-
ferase (i.e., acivicin), of the dipeptidase
(i.e., 1,10-phenanthroline or phenylalanyl-
glycine), the P-lyase (i.e., aminooxyacetic
acid), of HAO (i.e., hydroxybutynoate),
and the S-oxidase (i.e., methimazole) have
shown a direct dependence ofgeneration of
a reactive metabolite and consequent
nephrotoxicity in vivo, cytotoxicity in vitro,
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Figure 6. Strategies for elucidation of renal bioactiva-
tion and nephrotoxicity mechanisms. Scheme showing
processes whose roles in the nephrotoxicity of reduced
glutathione and cysteine S-conjugates have been stud-
ied. Abbreviations: RSG, GSH S-conjugate; RSCG, cys-
teinylglycine S-conjugate; RSC, cysteine S-conjugate;
RSNAcC, mercapturate; RSMC, a-methylcysteine S-
conjugate; GlyGly, glycylglycine; PheGly, L-pheny-
lalanylglycine; GGTase, y-glutamyltransferase; HAO,
L-2-hydroxy (2-amino) acid oxidase.
or nephrocarcinogenicity on these reaction
processes. It is clear, then, that with the
exception ofthose S-conjugates that form
reactive episulfonium ions, other nephro-
toxic cysteine S-conjugates must be metab-
olized to produce toxicity.
Conclusions
The concept ofmetabolism as a means by
which many chemicals are biotransformed
to reactive and toxic species is critical for
an understanding of most types ofchemi-
cal-induced nephrotoxicity. Mammalian
kidney possesses numerous enzymatic reac-
tions that can bioactivate chemicals. Several
bioactivation and detoxification pathways
are present simultaneously and compete for
the same substrates. An important consid-
eration is species differences. While not as
much information is available about drug
metabolism in human tissues, many ofthe
principles discovered in experimental ani-
mals are applicable. Care must be used in
extrapolating data from animals to humans
when assessing risk.
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